A bill to overhaul the 340B drug discount program has been introduced, marking a significant policy push that could reshape how hospitals and clinics purchase prescription drugs. The legislation targets a program that has long been a source of contention between drugmakers and health providers.
The 340B program requires drug manufacturers to sell outpatient drugs at discounted prices to hospitals and clinics serving low-income and uninsured patients. Critics argue it has expanded beyond its original intent, generating profits for some providers rather than directly benefiting patients.
While the bill's specific provisions remain under review, the proposal signals growing congressional interest in reining in the program's scope. Drugmakers have long sought tighter restrictions, while hospitals warn that deep cuts could threaten access to care for vulnerable populations.
Separately, a new candidate for FDA commissioner has emerged in the ongoing search for a permanent agency head. The nomination process comes at a critical time, with the agency facing decisions on drug approvals and regulatory policy.
The dual developments underscore the complex interplay between drug pricing and federal oversight. Both the 340B bill and the FDA appointment will face scrutiny from industry stakeholders and patient advocates. An earlier effort to overhaul the program stalled amid lobbying from both sides, raising questions about whether this proposal can gain traction.